Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-01 first-line LY3537982 combinations in KRAS G12C-mutant advanced non-small cell lung cancer
2023-503412-33-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of olomorasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503412-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503412-33-00.